S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
S&P 500   3,841.94 (+1.95%)
DOW   31,496.30 (+1.85%)
QQQ   308.68 (+1.51%)
AAPL   121.42 (+1.07%)
MSFT   231.60 (+2.15%)
FB   264.28 (+2.58%)
GOOGL   2,097.07 (+3.10%)
TSLA   597.95 (-3.78%)
AMZN   3,000.46 (+0.77%)
NVDA   498.46 (+0.74%)
BABA   233.89 (+1.47%)
CGC   31.17 (+0.52%)
GE   13.60 (+0.29%)
MU   88.93 (+5.45%)
NIO   38.11 (-2.98%)
AMD   78.52 (+0.99%)
T   29.62 (+2.42%)
F   12.27 (+2.85%)
ACB   9.60 (-2.24%)
DIS   189.99 (+1.04%)
BA   223.22 (-0.66%)
NFLX   516.39 (+1.00%)
BAC   36.93 (+1.18%)
Log in
NASDAQ:PSTV

Plus Therapeutics Stock Forecast, Price & News

$2.80
+0.57 (+25.56 %)
(As of 03/5/2021 12:00 AM ET)
Add
Compare
Today's Range
$2.26
Now: $2.80
$2.82
50-Day Range
$2.23
MA: $2.85
$3.75
52-Week Range
$0.93
Now: $2.80
$5.42
Volume1.13 million shs
Average Volume1.09 million shs
Market Capitalization$59.10 million
P/E RatioN/A
Dividend YieldN/A
Beta0.34
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and manufacture of treatments for cancer and other diseases. Its lead product candidate is DocePLUS, a protein-stabilized PEGylated liposomal formulation of docetaxel for the treatment of small cell lung cancer. The company is also involved in developing DoxoPLUS, a generic PEGylated liposomal encapsulated doxorubicin to treat breast and ovarian cancer, multiple myeloma, and Kaposi's sarcoma. It has a license agreement with NanoTx, Corp. to develop and commercialize NanoTx's glioblastoma treatment. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.
Plus Therapeutics logo

Headlines

Insider Buys Plus Therapeutics Stock
December 14, 2020 |  benzinga.com
Insider Buys Plus Therapeutics Shares
December 2, 2020 |  benzinga.com
A Look Into Plus Therapeutics's Price Over Earnings
September 1, 2020 |  benzinga.com
See More Headlines

Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:PSTV
CUSIPN/A
CIKN/A
Phone737-255-7194
Employees12
Year FoundedN/A

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$7 million
Book Value$0.31 per share

Profitability

Net Income$-10,890,000.00

Miscellaneous

Market Cap$59.10 million
Next Earnings Date5/13/2021 (Estimated)
OptionableNot Optionable

MarketRank

Overall MarketRank

1.49 out of 5 stars

Medical Sector

508th out of 1,972 stocks

Surgical & Medical Instruments Industry

46th out of 169 stocks

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 0.0 5 -4 -3 -2 -1 -
$2.80
+0.57 (+25.56 %)
(As of 03/5/2021 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive PSTV News and Ratings via Email

Sign-up to receive the latest news and ratings for PSTV and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Plus Therapeutics (NASDAQ:PSTV) Frequently Asked Questions

Is Plus Therapeutics a buy right now?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Plus Therapeutics in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Plus Therapeutics stock.
View analyst ratings for Plus Therapeutics
or view top-rated stocks.

What stocks does MarketBeat like better than Plus Therapeutics?

Wall Street analysts have given Plus Therapeutics a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Plus Therapeutics wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Plus Therapeutics?

Plus Therapeutics saw a increase in short interest during the month of January. As of January 29th, there was short interest totaling 150,300 shares, an increase of 440.6% from the January 14th total of 27,800 shares. Based on an average daily trading volume, of 399,900 shares, the short-interest ratio is presently 0.4 days. Approximately 3.3% of the company's shares are short sold.
View Plus Therapeutics' Short Interest
.

When is Plus Therapeutics' next earnings date?

Plus Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 13th 2021.
View our earnings forecast for Plus Therapeutics
.

How were Plus Therapeutics' earnings last quarter?

Plus Therapeutics, Inc. (NASDAQ:PSTV) announced its earnings results on Monday, February, 22nd. The company reported ($0.73) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.33) by $0.40. Plus Therapeutics had a negative net margin of 24.23% and a negative trailing twelve-month return on equity of 208.43%.
View Plus Therapeutics' earnings history
.

How has Plus Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Plus Therapeutics' stock was trading at $1.42 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, PSTV stock has increased by 97.2% and is now trading at $2.80.
View which stocks have been most impacted by COVID-19
.

What price target have analysts set for PSTV?

3 equities research analysts have issued 1 year price objectives for Plus Therapeutics' stock. Their forecasts range from $6.00 to $8.00. On average, they expect Plus Therapeutics' stock price to reach $7.00 in the next twelve months. This suggests a possible upside of 150.0% from the stock's current price.
View analysts' price targets for Plus Therapeutics
or view top-rated stocks among Wall Street analysts.

Who are Plus Therapeutics' key executives?

Plus Therapeutics' management team includes the following people:
  • Dr. Marc H. Hedrick M.D., Pres, CEO & Director (Age 58, Pay $867.43k)
  • Mr. Andrew J. Sims, VP of Fin. & CFO (Age 48)
  • Ms. Desiree Smith, Corp. Controller, Principal Financial & Accounting Officer (Age 57)
  • Dr. John K. Fraser, Chief Scientist (Age 60)
  • Mr. Russ Havranek M.B.A., M.S., VP of Corp. Strategy, New Product Planning & Investor Relations
  • Mr. Gary S. Titus CPA, Advisor (Age 61)
  • Dr. Gregory Stein, Sr. VP of Clinical Devel.

Who are some of Plus Therapeutics' key competitors?

What other stocks do shareholders of Plus Therapeutics own?

What is Plus Therapeutics' stock symbol?

Plus Therapeutics trades on the NASDAQ under the ticker symbol "PSTV."

Who are Plus Therapeutics' major shareholders?

Plus Therapeutics' stock is owned by many different retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.22%), Virtu Financial LLC (0.38%) and Creative Planning (0.29%). Company insiders that own Plus Therapeutics stock include Greg Petersen, Howard Clowes, Marc H Hedrick and Robert P Lenk.
View institutional ownership trends for Plus Therapeutics
.

Which institutional investors are selling Plus Therapeutics stock?

PSTV stock was sold by a variety of institutional investors in the last quarter, including Virtu Financial LLC.
View insider buying and selling activity for Plus Therapeutics
or view top insider-selling stocks.

Which institutional investors are buying Plus Therapeutics stock?

PSTV stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, and Creative Planning. Company insiders that have bought Plus Therapeutics stock in the last two years include Greg Petersen, Howard Clowes, Marc H Hedrick, and Robert P Lenk.
View insider buying and selling activity for Plus Therapeutics
or or view top insider-buying stocks.

How do I buy shares of Plus Therapeutics?

Shares of PSTV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Plus Therapeutics' stock price today?

One share of PSTV stock can currently be purchased for approximately $2.80.

How much money does Plus Therapeutics make?

Plus Therapeutics has a market capitalization of $59.10 million and generates $7 million in revenue each year.

How many employees does Plus Therapeutics have?

Plus Therapeutics employs 12 workers across the globe.

What is Plus Therapeutics' official website?

The official website for Plus Therapeutics is www.plustherapeutics.com.

Where are Plus Therapeutics' headquarters?

Plus Therapeutics is headquartered at 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756.

How can I contact Plus Therapeutics?

Plus Therapeutics' mailing address is 4200 MARATHON BLVD SUITE 200, AUSTIN TX, 78756. The company can be reached via phone at 737-255-7194 or via email at [email protected]


This page was last updated on 3/5/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.